Results 1 to 10 of about 3,638 (152)

Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease. [PDF]

open access: yesMol Genet Metab Rep
Okamoto H, Goto S, Fujita M, Fujii H.
europepmc   +1 more source

Effectiveness and tolerability of migalastat in adult Fabry disease: A single regional centre experience. [PDF]

open access: yesMol Genet Metab Rep
McCarron EP   +7 more
europepmc   +1 more source

Coexistence of Alport Syndrome and Fabry Disease in a Female with R112H Variant: Early Progression of Fabry Nephropathy. [PDF]

open access: yesInt J Mol Sci
Grimaldi A   +10 more
europepmc   +1 more source

Sex-based antibody subclass maturation drives direct enzymatic inhibition in fabry disease patients receiving enzyme replacement therapy. [PDF]

open access: yesFront Mol Biosci
Baldwin T   +18 more
europepmc   +1 more source

Prevalence and sociodemographic, clinical, and genetic characteristics of Fabry disease in north-central Chile, 2013-2023. [PDF]

open access: yesMol Genet Metab Rep
Royo Martínez S   +4 more
europepmc   +1 more source

Evaluation of <i>GLA</i> variants detected in newborn screening for Fabry disease using biomarker analysis. [PDF]

open access: yesMol Genet Metab Rep
Sawada T   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy